Alpha Cognition Announces Board Changes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: Newsfilter
- Board Leadership Change: Alpha Cognition has elected Robert Wills as Chairman of the Board, succeeding Len Mertz, who retired after serving since 2021, with Wills' extensive experience expected to provide strategic guidance for the company's future growth.
- Strategic Development Phase: Having served on the Board since 2025, Wills is poised to lead the company through a critical period as it commercializes ZUNVEYL, aiming to advance treatments for neurodegenerative diseases.
- Governance Enhancement: Under Mertz's leadership, Alpha Cognition strengthened its corporate governance framework and achieved several key operational and strategic milestones, with Wills' succession expected to continue this momentum and ensure competitiveness in the industry.
- New Drug Launch: ZUNVEYL, a newly approved treatment for Alzheimer's disease, will benefit from Wills' leadership in driving market adoption and patient acceptance, further solidifying the company's position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACOG
Wall Street analysts forecast ACOG stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.790
Low
18.00
Averages
18.00
High
18.00
Current: 7.790
Low
18.00
Averages
18.00
High
18.00
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Cognition Announces Board Changes
- Board Leadership Change: Alpha Cognition has elected Robert Wills as Chairman of the Board, succeeding Len Mertz, who retired after serving since 2021, with Wills' extensive experience expected to provide strategic guidance for the company's future growth.
- Strategic Development Phase: Having served on the Board since 2025, Wills is poised to lead the company through a critical period as it commercializes ZUNVEYL, aiming to advance treatments for neurodegenerative diseases.
- Governance Enhancement: Under Mertz's leadership, Alpha Cognition strengthened its corporate governance framework and achieved several key operational and strategic milestones, with Wills' succession expected to continue this momentum and ensure competitiveness in the industry.
- New Drug Launch: ZUNVEYL, a newly approved treatment for Alzheimer's disease, will benefit from Wills' leadership in driving market adoption and patient acceptance, further solidifying the company's position in the biopharmaceutical sector.
See More
Alpha Cognition Launches RESOLVE Study for ZUNVEYL
- Study Launch: Alpha Cognition announced the enrollment of the first patient in the RESOLVE study, which aims to evaluate the tolerability of ZUNVEYL in Alzheimer's patients, with approximately 150 patients expected to be enrolled, demonstrating the company's commitment to long-term drug efficacy.
- Clear Research Objectives: The RESOLVE study will collect safety and tolerability data while exploring changes in neuropsychiatric symptoms related to Alzheimer's disease, which not only aids physicians in making informed treatment decisions but also enhances patient treatment experiences.
- Data Complementation: Data generated from this study will complement previous clinical findings, further supporting the use of ZUNVEYL in clinical practice, reflecting the company's ongoing commitment to drug development.
- Long-Term Outlook: Alpha Cognition expects patient enrollment to continue through the second quarter of 2027, with study results providing crucial evidence for the market promotion of ZUNVEYL, aiding the company's strategic positioning in the neurodegenerative disease treatment sector.
See More
Alpha Cognition Q1 Earnings Beat Expectations
- Earnings Beat Expectations: Alpha Cognition reported a Q1 GAAP EPS of -$0.32, exceeding market expectations by $0.08, indicating improvements in cost management despite still being in a loss position.
- Revenue Misses Slightly: The reported revenue of $3.54M fell short of the anticipated $3.63M, reflecting challenges in sales growth that could impact investor confidence moving forward.
- Market Reaction Analysis: While the earnings beat may provide some positive sentiment, the revenue miss could lead to short-term stock price volatility, prompting investors to closely monitor the company's strategic adjustments and market performance.
- Future Outlook: The company needs to enhance its sales strategies to boost revenue and ensure sustained growth in a competitive market, particularly focusing on new product launches and market expansion.
See More
Alpha Cognition to Host Q1 2026 Earnings Call on May 14
- Earnings Release Schedule: Alpha Cognition Inc. will report its Q1 2026 financial results and provide a business update on May 14, 2026, at 4:30 PM ET, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will host a conference call for detailed discussions on financial and operational results, with participants able to join via 1-877-407-9039 or 1-201-689-8470, enhancing transparency and investor engagement.
- New Drug Development Progress: Alpha Cognition is developing ZUNVEYL®, a next-generation treatment for Alzheimer's disease, which is anticipated to fill a market gap with minimal gastrointestinal side effects and a unique mechanism of action, presenting substantial commercial potential.
- Forward-Looking Statements: The news release includes forward-looking statements that highlight potential market risks and uncertainties, urging investors to consider various factors that may affect the company's future performance.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
Alpha Cognition Grants Stock Options to New Employee
- Stock Option Grant: On April 14, 2026, Alpha Cognition granted 20,000 nonstatutory stock options to a new non-executive employee, aimed at attracting talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $6.49 per share, based on the closing price on April 14, 2025, which helps incentivize employees to grow alongside the company.
- Vesting Arrangement: The stock options will vest over three years, with 25% vesting after one year and the remainder vesting monthly, ensuring long-term employee commitment and contribution.
- Company Background: Alpha Cognition focuses on developing treatments for Alzheimer's disease and mild traumatic brain injury, with ZUNVEYL as a new generation drug expected to have minimal gastrointestinal side effects, showcasing the company's innovative potential in neurodegenerative diseases.
See More
Alpha Cognition Announces Board Changes
- Board Leadership Change: Alpha Cognition has elected Robert Wills as Chairman of the Board, succeeding Len Mertz, who retired after serving since 2021, with Wills' extensive experience expected to provide strategic guidance for the company's future growth.
- Strategic Development Phase: Having served on the Board since 2025, Wills is poised to lead the company through a critical period as it commercializes ZUNVEYL, aiming to advance treatments for neurodegenerative diseases.
- Governance Enhancement: Under Mertz's leadership, Alpha Cognition strengthened its corporate governance framework and achieved several key operational and strategic milestones, with Wills' succession expected to continue this momentum and ensure competitiveness in the industry.
- New Drug Launch: ZUNVEYL, a newly approved treatment for Alzheimer's disease, will benefit from Wills' leadership in driving market adoption and patient acceptance, further solidifying the company's position in the biopharmaceutical sector.
See More
Alpha Cognition Launches RESOLVE Study for ZUNVEYL
- Study Launch: Alpha Cognition announced the enrollment of the first patient in the RESOLVE study, which aims to evaluate the tolerability of ZUNVEYL in Alzheimer's patients, with approximately 150 patients expected to be enrolled, demonstrating the company's commitment to long-term drug efficacy.
- Clear Research Objectives: The RESOLVE study will collect safety and tolerability data while exploring changes in neuropsychiatric symptoms related to Alzheimer's disease, which not only aids physicians in making informed treatment decisions but also enhances patient treatment experiences.
- Data Complementation: Data generated from this study will complement previous clinical findings, further supporting the use of ZUNVEYL in clinical practice, reflecting the company's ongoing commitment to drug development.
- Long-Term Outlook: Alpha Cognition expects patient enrollment to continue through the second quarter of 2027, with study results providing crucial evidence for the market promotion of ZUNVEYL, aiding the company's strategic positioning in the neurodegenerative disease treatment sector.
See More
Alpha Cognition Q1 Earnings Beat Expectations
- Earnings Beat Expectations: Alpha Cognition reported a Q1 GAAP EPS of -$0.32, exceeding market expectations by $0.08, indicating improvements in cost management despite still being in a loss position.
- Revenue Misses Slightly: The reported revenue of $3.54M fell short of the anticipated $3.63M, reflecting challenges in sales growth that could impact investor confidence moving forward.
- Market Reaction Analysis: While the earnings beat may provide some positive sentiment, the revenue miss could lead to short-term stock price volatility, prompting investors to closely monitor the company's strategic adjustments and market performance.
- Future Outlook: The company needs to enhance its sales strategies to boost revenue and ensure sustained growth in a competitive market, particularly focusing on new product launches and market expansion.
See More
Alpha Cognition to Host Q1 2026 Earnings Call on May 14
- Earnings Release Schedule: Alpha Cognition Inc. will report its Q1 2026 financial results and provide a business update on May 14, 2026, at 4:30 PM ET, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will host a conference call for detailed discussions on financial and operational results, with participants able to join via 1-877-407-9039 or 1-201-689-8470, enhancing transparency and investor engagement.
- New Drug Development Progress: Alpha Cognition is developing ZUNVEYL®, a next-generation treatment for Alzheimer's disease, which is anticipated to fill a market gap with minimal gastrointestinal side effects and a unique mechanism of action, presenting substantial commercial potential.
- Forward-Looking Statements: The news release includes forward-looking statements that highlight potential market risks and uncertainties, urging investors to consider various factors that may affect the company's future performance.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
Alpha Cognition Grants Stock Options to New Employee
- Stock Option Grant: On April 14, 2026, Alpha Cognition granted 20,000 nonstatutory stock options to a new non-executive employee, aimed at attracting talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $6.49 per share, based on the closing price on April 14, 2025, which helps incentivize employees to grow alongside the company.
- Vesting Arrangement: The stock options will vest over three years, with 25% vesting after one year and the remainder vesting monthly, ensuring long-term employee commitment and contribution.
- Company Background: Alpha Cognition focuses on developing treatments for Alzheimer's disease and mild traumatic brain injury, with ZUNVEYL as a new generation drug expected to have minimal gastrointestinal side effects, showcasing the company's innovative potential in neurodegenerative diseases.
See More
